U.S. License Holder:
Acendis Pharma Endocrinology Div A/S
Date of License:
August-25-2021
Last Update:
Dec-15-2024
FDA-Approved Indications
SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).